Actions of Thyroid Hormones on Thyroid Cancers
Open Access
- 21 June 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Abstract
L-Thyroxine (T4) is the principal ligand of the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3. The integrin is overexpressed and activated in cancer cells, rapidly dividing endothelial cells, and platelets. The biologic result is that T4 at physiological concentration and without conversion to 3,3’,5-triiodo-L-thyronine (T3) may stimulate cancer cell proliferation and cancer-relevant angiogenesis and platelet coagulation. Pro-thrombotic activity of T4 on platelets is postulated to support cancer-linked blood clotting and to contribute to tumor cell metastasis. We examine some of these findings as they may relate to cancers of the thyroid. Differentiated thyroid cancer cells respond to physiological levels of T4 with increased proliferation. Thus, the possibility exists that in patients with differentiated thyroid carcinomas in whom T4 administration and consequent endogenous thyrotropin suppression have failed to arrest the disease, T4 treatment may be stimulating tumor cell proliferation. In vitro studies have shown that tetraiodothyroacetic acid (tetrac), a derivative of T4, acts via the integrin to block T4 support of thyroid cancer and other solid tumor cells. Actions of T4 and tetrac or chemically modified tetrac modulate gene expression in thyroid cancer cells. T4 induces radioresistance via induction of a conformational change in the integrin in various cancer cells, although not yet established in thyroid cancer cells. The thyroid hormone receptor on integrin αvβ3 mediates a number of actions of T4 on differentiated thyroid cancer cells that support the biology of the cancer. Additional studies are required to determine whether T4 acts on thyroid cancer cells.Keywords
This publication has 57 references indexed in Scilit:
- Nongenomic Actions of Thyroid Hormone: The Integrin ComponentPhysiological Reviews, 2021
- Radioresistance of cancer cells, integrin αvβ3 and thyroid hormoneOncotarget, 2018
- Activation of tumor cell integrin αvβ3 by radiation and reversal of activation by chemically modified tetraiodothyroacetic acid (tetrac)Endocrine Research, 2018
- Nongenomic actions of thyroid hormoneNature Reviews Endocrinology, 2015
- Thyroid hormone and anti-apoptosis in tumor cellsOncotarget, 2015
- Modulation of angiogenesis by thyroid hormone and hormone analogues: implications for cancer managementAngiogenesis, 2014
- Thyroid Hormone, Hormone Analogs, and Angiogenesis2011
- Molecular Aspects of Thyroid Hormone ActionsEndocrine Reviews, 2010
- Integrins in cancer: biological implications and therapeutic opportunitiesNature Reviews Cancer, 2010
- Integrin αVβ3 Contains a Cell Surface Receptor Site for Thyroid Hormone that Is Linked to Activation of Mitogen-Activated Protein Kinase and Induction of AngiogenesisEndocrinology, 2005